Suppr超能文献

痛泻要方联合四逆散治疗肠易激综合征的有效性:一项系统评价与Meta分析方案

Effectiveness of Tong-Xie-Yao-Fang combined with Si-Ni-San for irritable bowel syndrome: A protocol for systematic review and meta-analysis.

作者信息

Jiang Jiawang, Chen Yun, Hu Ziyi, Li Huaiyu, Ye Jing, Yu Zhiying, Tang Haiyi

机构信息

Jiangxi University of Traditional Chinese Medicine, Nanchang.

First Affiliated Hospital of Gannan Medical University, Ganzhou.

出版信息

Medicine (Baltimore). 2021 Mar 19;100(11):e25198. doi: 10.1097/MD.0000000000025198.

Abstract

BACKGROUND

Irritable bowel syndrome (IBS) has a high morbidity rate worldwide, but there are no effective treatment measures, which seriously affect people's lives. Previous clinical studies on Tong-Xie-Yao-Fang (TXYF) combined with Si-Ni-San (SNS) in the treatment of IBS have been increasing, but there is no systematic evaluation. This study aims to systematically study the effectiveness of TXYF combined with SNS in the treatment of IBS.

METHODS

The PubMed, EMBASE, Science Network, Cochrane Library, Chinese Biomedical Literature, Wanfang Chinese Digital Journal and Conference Database, China National Knowledge Infrastructure Database and VIP China Science and Technology Journal Database (VIP) will be used Search related literature, and the search time is from the date of establishment to February 2021. The National Institutes of Health clinical registry Clinical Trials, International Clinical Trials Registry Platform and the Chinese clinical trial registration platform will be searched to find ongoing or unpublished trials. After screening the literature according to the criteria, two researchers independently extracted data according to a predetermined table. The primary outcome is total effective rate. The RevMan 5.3.5 software will be used for statistical analysis. Finally, the recommendation, evaluation, development and evaluation system will be used to evaluate the quality evidence for each result.

RESULTS

This study will provide the latest evidence of efficacy for the TXYF combined with SNS for IBS.

CONCLUSION

The effectiveness of TXYF combined with SNS for IBS will be evaluated.

UNIQUE INPLASY NUMBER

INPLASY202120075.

摘要

背景

肠易激综合征(IBS)在全球发病率较高,但尚无有效治疗措施,严重影响人们的生活。以往关于痛泻要方(TXYF)联合四逆散(SNS)治疗IBS的临床研究不断增多,但缺乏系统评价。本研究旨在系统探讨TXYF联合SNS治疗IBS的有效性。

方法

将检索PubMed、EMBASE、科学网、Cochrane图书馆、中国生物医学文献数据库、万方中文数字化期刊及会议数据库、中国知网数据库和维普中国科技期刊数据库(VIP)等相关文献,检索时间从建库至2021年2月。检索美国国立卫生研究院临床注册库Clinical Trials、国际临床试验注册平台及中国临床试验注册平台,查找正在进行或未发表的试验。按照标准筛选文献后,两名研究人员根据预定表格独立提取数据。主要结局指标为总有效率。采用RevMan 5.3.5软件进行统计分析。最后,采用推荐、评价、制定与评价系统对各结果的质量证据进行评价。

结果

本研究将为TXYF联合SNS治疗IBS提供最新的疗效证据。

结论

将评价TXYF联合SNS治疗IBS的有效性。

唯一的INPLASY编号:INPLASY202120075。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0fee/7982163/51bc193edef8/medi-100-e25198-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验